publication venue for
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study.. 14. 2024
- Genomic and functional impact of Trp53 inactivation in JAK2V617F myeloproliferative neoplasms.. 14. 2024
- Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group.. 12. 2022
- Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies.. 12. 2022
- Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma.. 12. 2022
- ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine.. 11. 2021
- Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial.. 11. 2021
- OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia.. 11. 2021
- Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma.. 10. 2020
- Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups.. 10. 2020
- Nfkbie-deficiency leads to increased susceptibility to develop B-cell lymphoproliferative disorders in aged mice.. 10. 2020
- Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis.. 10. 2020
- Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse.. 9. 2019
- Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma.. 9. 2019
- Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma.. 8. 2018
- Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials.. 8. 2018
- Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay.. 8. 2018
- Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment.. 7. 2017
- Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells.. 6. 2016
- Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma.. 5. 2015
- An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies.. 5. 2015
- Hypermethylation of the tumor suppressor gene PRDM1/Blimp-1 supports a pathogenetic role in EBV-positive Burkitt lymphoma.. 4. 2014
- Pathogenetic and diagnostic significance of microRNA deregulation in peripheral T-cell lymphoma not otherwise specified.. 4. 2014
- Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma.. 4. 2014
- Variable risk of second primary malignancy in multiple myeloma patients of different ethnic subgroups.. 4. 2014
- Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma.. 4. 2014
- Cancer-testis antigen expression and immunogenicity in AL amyloidosis.. 2. 2012
- Analysis of genomic aberrations and gene expression profiling identifies novel lesions and pathways in myeloproliferative neoplasms.. 1. 2011
- Further phenotypic characterization of the primitive lineage- CD34+CD38-CD90+CD45RA- hematopoietic stem cell/progenitor cell sub-population isolated from cord blood, mobilized peripheral blood and patients with chronic myelogenous leukemia.. 1. 2011
- Targeted genomic analysis of cutaneous T cell lymphomas identifies a subset with aggressive clinicopathological features.. 10. 2020
- Exploring tumor clonal evolution in bone marrow of patients with diffuse large B-cell lymphoma by deep IGH sequencing and its potential relevance in relapse.. 9. 2019
- Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project.. 8. 2018
- Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care.. 7. 2017
- MicroRNA-155 regulates casein kinase 1 gamma 2: a potential pathogenetic role in chronic lymphocytic leukemia.. 7. 2017
- Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study.. 7. 2017
- Inactivation of BANK1 in a novel IGH-associated translocation t(4;14)(q24;q32) suggests a tumor suppressor role in B-cell lymphoma.. 4. 2014
- Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study. 2024
- Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group's clinical trial E3999. 2022
- Acute myeloid leukemia targets for bispecific antibodies. 2017